Edoxaban - Daiichi Sankyo Company

Drug Profile

Edoxaban - Daiichi Sankyo Company

Alternative Names: DU-176; DU-176b; Edoxaban tosilate hydrate; Edoxaban tosylate; LIXIANA; Lixiana; Lixiana OD; Roteas; SAVAYSA

Latest Information Update: 06 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antithrombotics; Small molecules
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atrial fibrillation; Embolism; Stroke; Venous thromboembolism
  • Registered Deep vein thrombosis; Pulmonary embolism
  • No development reported Venous thrombosis

Most Recent Events

  • 10 Jan 2018 Daiichi Sankyo plans a phase III trial for Cardiovascular disorder in February 2018 , (NCT03395639)
  • 13 Dec 2017 Efficacy data from the phase IIIb Hokusai-VTE CANCER trial in Venous thromboembolism presented at the 59th American Society of Hematology (ASH-2017) ,
  • 29 Nov 2017 Launched for Embolism (Prevention) in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top